FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2026 | $1,070,000 | Replaced |
| 1st Quarter - Amendment | Jun 18, 2026 | $1,100,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| SARAH CHRISTINE D'ORSIE | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
Medicare/Medicaid MMM
CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| SARAH CHRISTINE D'ORSIE | — |
Health Issues HCR
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
| STU EVENHAUGEN | — |
| CHRISTOPHER LEIBUNDGUTH | — |
| STEVEN CHASE WALKER | — |
Manufacturing MAN
Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| STU EVENHAUGEN | — |
Copyright/Patent/Trademark CPT
PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CHRISTINE D'ORSIE | — |
| STEVEN CHASE WALKER | — |
Taxation/Internal Revenue Code TAX
Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| CHRISTOPHER LEIBUNDGUTH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.